CME Information
Provider Statement: This continuing medical education activity is provided by 
.
Support Statement: This activity is supported by an educational grant from Merck & Co., Inc.
Target Audience: The intended audience for this activity is hematologist-oncologists, oncologists and other health care professionals involved in the management of patients with hepatocellular carcinoma (HCC).
Learning Objectives: Upon successful completion of this activity, participants should be able to:
- Assess the latest clinical evidence regarding targeted and/or immunotherapies for the management of patients with HCC and the associated implications for practice.
- Review the unique array of toxicities associated with newer targeted and immune-based therapies for the treatment of patients with advanced HCC as well as strategies for management.
Activity Chair:
Richard S. Finn, MD
Professor of Medicine
Geffen School of Medicine Department of Medicine, Division of Hematology/Oncology
University of California Los Angeles
Los Angeles, CA
Faculty:
Joseph M. Llovet, MD
Professor of Medicine
Professor of Research
Icahn School of Medicine at Mount Sinai
New York, NY
Andrew X. Zhu, MD, PhD
Professor of Medicine, Harvard Medical School
Director of Liver Cancer Research, Massachusetts General Hospital Cancer Center
Boston, MA
Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Accreditation:
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation:
Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, June 11, 2019, to June 10, 2020.
How To Participate in This Activity and Obtain CME Credit:
To participate in this CME activity, you must read the objectives, answer the pretest questions, review the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 out of 3 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™.
Disclosures:
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.
The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.
Activity Chair and Faculty report the following relationships:
Richard S. Finn, MD
Consulting Fee: AstraZeneca, Bayer, Bristol-Myers Squibb, Eisai, Merck, Novartis, Pfizer, Roche/Genentech
Joseph M. Llovet, MD
Consulting Fee: Bayer, Blueprint, Bristol-Myers Squibb, Can-Fite BioPharma, Celsion, Eisai, Eli Lilly, Exelixis, Fortress Biotech, Glycotest, Ipsen, Leerink Swann, Merck, Midatech, Navigant, Nucleix, Spring Bank Pharmaceuticals
Contracted Research (Paid to Institution): Bayer, Bristol-Myers Squibb, Eisai, Ipsen
Andrew X. Zhu, MD, PhD
Consulting Fee: Bayer, Bristol-Myers Squibb, Eisai, Lilly, Merck, Sanofi
Reviewer reports the following relationship(s):
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Vindico Medical Education staff report the following relationship(s):
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage:
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement:
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at cme@vindicoCME.com